The global rubella diagnostic testing market is expected to register significant growth over the forecast period, driven by rising prevalence of chronic diseases due to togavirus. Increasing incidences of rubella is a direct consequence of high transmission ability of togavirus via air. Rubella infection generally affects children and adults. The infection has serious implications in pregnant women, which can lead to fetal death or congenital defects. Increasing demand for MMR vaccines for the protection of children against rubella and introduction of advanced point of care diagnostic technologies such as BioPlex 2200 MMRV (varicella zoster, rubella, mumps and measles virus) by Bio Rad Laboratories are additionally propelling the growth of global rubella diagnostic testing market. In a probe to combat rubella disease, various government initiatives pertaining to research and development of advanced diagnostic techniques in emerging countries such as China and India are carried out, which is in turn expected to propel growth of market in near future. However, there is no typical drug therapy available for treatment of rubella in present, which is expected to restrain the growth of rubella diagnostic testing market over the forecast period.
The overall rubella diagnostic testing market is categorized on the basis of diagnostic testing techniques into flow cytometry, latex slide agglutination test, monoclonal antibodies, immunoassays, serological testing, and clinical evaluation. These tests are typically prescribed for pregnant women along with women planning to conceive and health professionals who are in contact with pregnant women. These tests may also be performed for babies born with congenital defects.
Geographically, the entire rubella diagnostic testing market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, Europe was one of the largest market in terms of revenue share owing to the increased cases of rubella infection in this region. According to the Pan American Health Organization (PAHO) and WHO, Colombia and Latin America are declared free of rubella infection, as of 2011. However, epidemics of rubella are still present in developing regions such as Africa and South East Asia. Vaccination for rubella are not available in these regions. Thailand, Timor Leste, Macedonia, Tajikistan, and Syria are accounted for largest number of rubella infection cases as of 2013. Asia Pacific region is expected to register lucrative growth over the forecast period owing to larger untapped opportunities, increasing government initiatives for development of novel vaccines and therapies, and comparatively lower cost of production.
The global rubella diagnostic testing market is highly fragmented due to the engagement of various established as well as emerging players in the market. Some key players operating in the market include Ortho Clinical Diagnostics, Merck & Co., Siemens AG, GlaxoSmithKline plc., Hoffmann La Roche Ltd., Bio Rad Laboratories, Inc., BioMerieux SA, Beckman Coulter Inc., and Abbott Laboratories. These companies are constantly involved in R&D for gaining competitive advantage in the global market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.